Eli Lilly CEO Expresses Disappointment Over Low GLP-1 Drug Adoption in US

Eli Lilly's CEO has voiced disappointment that only a small fraction of Americans are currently using GLP-1 medications, a class of drugs used for conditions like diabetes and weight loss. The statement highlights concerns about the accessibility or uptake of these treatments.